![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SKP2 |
Gene summary for SKP2 |
![]() |
Gene information | Species | Human | Gene symbol | SKP2 | Gene ID | 6502 |
Gene name | S-phase kinase associated protein 2 | |
Gene Alias | FBL1 | |
Cytomap | 5p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q13309 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6502 | SKP2 | LZE4T | Human | Esophagus | ESCC | 1.83e-06 | 2.31e-01 | 0.0811 |
6502 | SKP2 | LZE7T | Human | Esophagus | ESCC | 2.12e-05 | 4.71e-01 | 0.0667 |
6502 | SKP2 | LZE8T | Human | Esophagus | ESCC | 7.53e-04 | 2.65e-01 | 0.067 |
6502 | SKP2 | LZE20T | Human | Esophagus | ESCC | 6.33e-03 | 1.66e-01 | 0.0662 |
6502 | SKP2 | LZE24T | Human | Esophagus | ESCC | 5.92e-04 | 1.91e-01 | 0.0596 |
6502 | SKP2 | LZE6T | Human | Esophagus | ESCC | 1.80e-10 | 6.53e-01 | 0.0845 |
6502 | SKP2 | P1T-E | Human | Esophagus | ESCC | 1.70e-04 | 2.39e-01 | 0.0875 |
6502 | SKP2 | P2T-E | Human | Esophagus | ESCC | 5.35e-23 | 4.53e-01 | 0.1177 |
6502 | SKP2 | P4T-E | Human | Esophagus | ESCC | 4.41e-15 | 4.39e-01 | 0.1323 |
6502 | SKP2 | P5T-E | Human | Esophagus | ESCC | 5.11e-05 | 1.79e-01 | 0.1327 |
6502 | SKP2 | P8T-E | Human | Esophagus | ESCC | 7.99e-12 | 2.68e-01 | 0.0889 |
6502 | SKP2 | P9T-E | Human | Esophagus | ESCC | 3.15e-03 | 1.08e-01 | 0.1131 |
6502 | SKP2 | P10T-E | Human | Esophagus | ESCC | 8.08e-38 | 7.52e-01 | 0.116 |
6502 | SKP2 | P11T-E | Human | Esophagus | ESCC | 8.61e-08 | 4.45e-01 | 0.1426 |
6502 | SKP2 | P12T-E | Human | Esophagus | ESCC | 9.23e-11 | 2.45e-01 | 0.1122 |
6502 | SKP2 | P15T-E | Human | Esophagus | ESCC | 3.60e-04 | 1.54e-01 | 0.1149 |
6502 | SKP2 | P16T-E | Human | Esophagus | ESCC | 2.84e-18 | 3.30e-01 | 0.1153 |
6502 | SKP2 | P17T-E | Human | Esophagus | ESCC | 4.81e-07 | 3.66e-01 | 0.1278 |
6502 | SKP2 | P20T-E | Human | Esophagus | ESCC | 2.43e-11 | 3.70e-01 | 0.1124 |
6502 | SKP2 | P21T-E | Human | Esophagus | ESCC | 1.50e-25 | 6.24e-01 | 0.1617 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005160711 | Oral cavity | LP | defense response to virus | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
GO:014054611 | Oral cavity | LP | defense response to symbiont | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
GO:0031668110 | Oral cavity | LP | cellular response to extracellular stimulus | 91/4623 | 246/18723 | 1.07e-05 | 1.94e-04 | 91 |
GO:190332215 | Oral cavity | LP | positive regulation of protein modification by small protein conjugation or removal | 57/4623 | 138/18723 | 1.24e-05 | 2.23e-04 | 57 |
GO:007093616 | Oral cavity | LP | protein K48-linked ubiquitination | 32/4623 | 65/18723 | 1.61e-05 | 2.81e-04 | 32 |
GO:000008213 | Oral cavity | LP | G1/S transition of mitotic cell cycle | 80/4623 | 214/18723 | 2.30e-05 | 3.74e-04 | 80 |
GO:004484313 | Oral cavity | LP | cell cycle G1/S phase transition | 88/4623 | 241/18723 | 2.62e-05 | 4.21e-04 | 88 |
GO:003052013 | Oral cavity | LP | intracellular estrogen receptor signaling pathway | 26/4623 | 54/18723 | 1.57e-04 | 1.78e-03 | 26 |
GO:003139815 | Oral cavity | LP | positive regulation of protein ubiquitination | 47/4623 | 119/18723 | 2.46e-04 | 2.60e-03 | 47 |
GO:000020915 | Oral cavity | LP | protein polyubiquitination | 82/4623 | 236/18723 | 3.23e-04 | 3.26e-03 | 82 |
GO:007138319 | Oral cavity | LP | cellular response to steroid hormone stimulus | 71/4623 | 204/18723 | 7.42e-04 | 6.62e-03 | 71 |
GO:003052219 | Oral cavity | LP | intracellular receptor signaling pathway | 87/4623 | 265/18723 | 1.63e-03 | 1.25e-02 | 87 |
GO:003051817 | Oral cavity | LP | intracellular steroid hormone receptor signaling pathway | 43/4623 | 116/18723 | 1.99e-03 | 1.47e-02 | 43 |
GO:004340117 | Oral cavity | LP | steroid hormone mediated signaling pathway | 48/4623 | 136/18723 | 3.60e-03 | 2.39e-02 | 48 |
GO:00331461 | Oral cavity | LP | regulation of intracellular estrogen receptor signaling pathway | 16/4623 | 35/18723 | 5.39e-03 | 3.29e-02 | 16 |
GO:003314314 | Oral cavity | LP | regulation of intracellular steroid hormone receptor signaling pathway | 28/4623 | 74/18723 | 8.17e-03 | 4.44e-02 | 28 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa052229 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa0522216 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa040684 | Liver | HCC | FoxO signaling pathway | 85/4020 | 131/8465 | 3.99e-05 | 2.16e-04 | 1.20e-04 | 85 |
hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SKP2 | SNV | Missense_Mutation | novel | c.28N>A | p.Pro10Thr | p.P10T | Q13309 | protein_coding | deleterious(0.01) | benign(0.232) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SKP2 | insertion | Frame_Shift_Ins | novel | c.665_666insTTTAAAGCCTATGGTAGGTTATCTGTGCAGTGTGGGA | p.Val223LeufsTer26 | p.V223Lfs*26 | Q13309 | protein_coding | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
SKP2 | SNV | Missense_Mutation | c.484N>T | p.Ala162Ser | p.A162S | Q13309 | protein_coding | tolerated(0.34) | benign(0.034) | TCGA-AA-3855-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SKP2 | SNV | Missense_Mutation | rs752559772 | c.535N>G | p.Ser179Gly | p.S179G | Q13309 | protein_coding | tolerated(0.39) | benign(0.001) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
SKP2 | SNV | Missense_Mutation | novel | c.313N>T | p.Leu105Phe | p.L105F | Q13309 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SKP2 | SNV | Missense_Mutation | rs759798637 | c.674N>T | p.Thr225Ile | p.T225I | Q13309 | protein_coding | deleterious(0.01) | benign(0.03) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SKP2 | SNV | Missense_Mutation | novel | c.66N>T | p.Trp22Cys | p.W22C | Q13309 | protein_coding | deleterious(0.05) | probably_damaging(0.956) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SKP2 | SNV | Missense_Mutation | novel | c.987N>T | p.Gln329His | p.Q329H | Q13309 | protein_coding | tolerated(0.18) | benign(0.143) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
SKP2 | SNV | Missense_Mutation | novel | c.234N>A | p.Asp78Glu | p.D78E | Q13309 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SKP2 | SNV | Missense_Mutation | novel | c.247N>T | p.Arg83Cys | p.R83C | Q13309 | protein_coding | tolerated(0.06) | benign(0.045) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |